Increase in insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 1 after supplementation with selenium and coenzyme Q10. A prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens

What Was Tested

Researchers studied IGF-1 LR3 in this randomized controlled trial publication.

Insulin-like growth factor-1(IGF-1) has a multitude of effects besides cell growth and metabolism.

Reports also indicate anti-inflammatory and antioxidative effects.

Who Took Part

The abstract describes 215 individuals taking part.

PubMed indexes the participants as older adults and people over 80, both men and women.

How the Study Was Run

In design terms this was a randomized and double-blind study.

The individuals were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.

Blinding on both sides kept the individuals and researchers unaware of who received IGF-1 LR3.

The timeline in the abstract includes four years.

215 elderly individuals were included and given the intervention for four years.

A clinical examination was performed and blood samples were taken at the start and after 48 months.

Evaluations of IGF-1, the age adjusted IGF-1 SD score and IGFBP-1 were performed using group mean values, and repeated measures of variance.

What Was Measured

PubMed files the paper under topics including Analysis of Variance, Dietary Supplements, Insulin-Like Growth Factor Binding Protein 1, Insulin-Like Growth Factor I, Postprandial Period, Selenium and Sweden.

What This Means in Plain Language

The paper is a randomized and double-blind study of IGF-1 LR3 in 215 individuals over four years.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (PloS one), a journal based in United States.

More context: the IGF-1 LR3 compound page, all human trials.